期刊文献+

补肾益肺消癥方干预肺纤维化大鼠TGFβ信号通路的作用机制 被引量:11

Functional Mechanism of prescription of nourishing lung and kidney and elimination on the intervention of signal pathway of TGF in pulmonary fibrosis rats
下载PDF
导出
摘要 目的:探讨补肾益肺消癥方治疗特发性肺纤维化疗效的作用机制。方法:以博莱霉素致大鼠肺纤维化为动物模型,补肾益肺消癥方进行干预;检测血清中TGF-b1含量的差异、肺组织中TGF-b1R基因表达的改变以及Smad2/3、Smad4蛋白含量的差异。结果:该方可以明显下调IPF大鼠外周血血清中TGF-b1的含量和Smad2、3的表达,对TGF-bR1基因表达无影响。结论:通过调控TGF-b信号传导通路,缓解炎症反应并抑制肺组织纤维化,是补肾益肺消癥方疗效的关键作用机制之一。 Objective: To explore the mechanism of Bushenyifeixiaozheng Formula in the treatment of idiopathic pulmonary fibrosis (IPF). Methods :The IPF rats were caused by Bleomycin and treated by Bushenyifeixiaozheng Formula. The contents of transforming growth factor (TGF)- bl in serum of rats were detected by enzyme linked immunosorbcnt assay (ELISA). The gene expression of TGF-bl receptor (TGF-blR) in lung of IPF rats was detected by real-time PCR. The protein contents of Smad2/3 and Smad4 were detected by western-blot. Results: TGF-blcontent in the serum of IPF rats was down regulated through treated by this formula, but the gene expression of TGF-bl R was no change. Smad2and Smad3 of the key molecules in TG-F-b signal pathway could be down regulated by this formula. Conclusion: This formula should interfere in the TGF-b signal pathway, release the inflammatory reaction and inhibit the process of pulmonary fibrosis. This should be the key mechanism of IPF treated by this formula.
出处 《中国中医基础医学杂志》 CAS CSCD 北大核心 2013年第9期778-780,786,共4页 JOURNAL OF BASIC CHINESE MEDICINE
基金 北京中医药大学中青年教师自主创新项目(JYB22-JS068)
关键词 补肾益肺消癥方 肺纤维化大鼠 TGF-b1信号传导通路 基因及蛋白表达 Bushenyifeixiaozheng Formula IPF rats TGF-b signal pathway Expression of gene and protein
  • 相关文献

参考文献10

  • 1Olson A L, Swigris J, Lezotte D C, et al. Mortality frompulmonary fibrosis increased in the United States from 1992-2003[J]. Am J Respir Crit Care Med, 2007 , 176(3):277-284.
  • 2柴立民,刘涓,王珍,晏军.从“肺络微型癥瘕”论治特发性肺纤维化[J].广西中医药,2012,35(2):44-45. 被引量:22
  • 3McKeown S, Richter AG, 0 ' Kane C, et al. Matrixmetalloproteinase expression and abnormal lung permeability areimportant determinants of outcome in IPF [ J]. Eur Respir J,2009,33(1) :77-84.
  • 4Daniil Z,Kitsanta P, Kapotsis G,et al. CD8 + T lymphocytesin lung tissue from patients with idiopathic pulmonary fibrosis[J]. Respiratory Research, 2005,6:81.
  • 5Duan W, So T, Mehta AK, et al. Inducible CD4 + LAP+Foxp3 ~ regulatory T cells suppress allergic inflammation [ J] . J_ Immunol, 2011,187(12) :6499-6507.
  • 6Oida T, Weiner HL. TGF-p induces surface LAP expression onmurine CD4 T cells independent of Foxp3 induction [ J]. PLoSOne, 2010, 5(11) ;el5523.
  • 7Yuan SM , Wang J, Hu XN, et al. Transforming growth factor-p/Smad signaling function in the aortopathies[ J]. Rev Bras CirCardiovasc, 2011, 26(3) :393403.
  • 8Sun H, Li D, Chen S,et al. Zili inhibits transforming growthfactor-beta signaling by interacting with Smad4 [ J]. J BiolChem, 2010,285(6) :42434250.
  • 9Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated genetransfer of active transforming growth factor-betal inducesprolonged severe fibrosis in rat lung[ J]. J. Clin. Invest, 1997,100(4) :768-776收稿日期:201343-26.
  • 10Frankel S L, Schwarz M I. Update in idiopathic pulmonaryfibrosis [J]. Curr Opin Pulm Med, 2009,15(5) :463-469.

二级参考文献9

共引文献21

同被引文献220

引证文献11

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部